Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | CLEOPATRA: changes in breast cancer natural history

Sandra Swain • 3 Jun 2019
ASCO 2019
Breast Cancer Docetaxel Pertuzumab Trastuzumab
CLEOPATRA

Sandra Swain, MD, FASCO, of the Georgetown University Medical Center, Washington, DC, outlines the end-of-study analysis of the CLEOPATRA (NCT00567190) breast cancer trial. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Sandra Swain

2:43
CLEOPATRA & EMILIA: HER2+ mBC state-of-the-art
Sandra Swain • 7 May 2020
1:56
NSABP B-41: genes and signatures associated with pCR
Sandra Swain • 7 May 2020
2:40
CLEOPATRA: pertuzumab, trastuzumab & chemo for HER2+ mBC
Sandra Swain • 8 May 2020
2:37
Remarkable data: trastuzumab deruxtecan for HER2+ BC
Sandra Swain • 13 May 2020

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals